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Ocular toxoplasmosis is the most frequent cause 
of posterior uveitis. [1] The parasite has an intracel-
lular cycle. During the primary infection, the subject is 
usually asymptomatic and can present flu-like 
symptoms. A dissemination of the parasites occurs 
and the tissular cysts will persist during the all life of 
the host. An ocular reactivation of the disease can 
occur when the cysts are present within the retina 
(Figure 1). The patients present a photophobia and 
floaters are seen. The slit-lamp examination reveals 
the presence of a granulomatous inflammation, a mild 
to moderate anterior chamber inflammation. Fundo-
scopy reveals the presence of a yellow focus of reti-
nochoroiditis. Recent epidemiological data have 
shown that most cases of ocular toxoplasmosis result 
from reactivation of ocular toxoplasmosis and not 
from primary infection. Disease evolution depends on 
many factors: the immune response of the host, the 
virulence of the parasite and environmental factors 
and ocular toxoplasmosis can heals spontaneously 
after two to three months even in the absence of 
therapy.  
A review of ophthalmic literature shows that no 
standard therapy could be proven by large multicen-
tric clinical trials. [2] A survey of the opinion of oph-
thalmic specialists in uveitis was performed recently 
by Gary Holland. [3] The reasons that were commonly 
accepted to introduce a therapy were the following: a) 
the presence of a lesion within the vascular arcades of 
the posterior pole (zone 1) b) the presence of a lesion 
in the proximity of the optic nerve or the macula c) or 
a severe inflammatory reaction within the eyes. The 
zone 1 area was defined as a lesion that was in a 
sight-threatning area and corresponding to an area 
extending 3000 μm (2 disk diameters) from the fovea 
(approximately that area enclosed by the major tem-
poral vascular arcades or 1500 μm from the margins of 
the optic disk.  
The prospective study performed by Perkins in 
1956 could not demonstrate the efficacy of daraprim 
in the therapy of ocular toxoplasmosis. But the out-
come was measured 4 weeks after initiation of ther-
apy. Dihydrofolate reductase inhibitors (DHFR) have 
shown their efficacy in vivo in the treatment of 
toxoplamosis. To increase the efficacy of therapy a 
combination of sulfadiazine and pyrimethamine was 
proposed since synergistic effect of these two drugs 
could be demonstrated in vitro. Pyrimethamine in-
terferes with the conversion of folic acid to folinic acid 
through dihydropteroate synthase (DHPS) whereas 
sulfonamide interferes with the formation of folic acid 
from para-amino benzoic acid. Human beings unlike 
T. gondii can utilize exogenous folinic acid for their 
cells.  
Classical therapy of ocular toxoplasmosis con-
sists in a association of 2 to 4.0 g of sulfadiazine 
loading dose given over 24 hours, followed by 1g 
given 4 times daily associated with 75mg to 100mg 
pyrimethamine loading dose initially followed by 25 
to 50 mg daily. Systemic steroids 1mg/kg is associ-
ated in the presence of severe ocular inflammation or 
in the presence of a zone 1 infection. A prospective 
randomised trial of trimethoprim/sulfamethoxazole 
versus pyrimethamine and sulfadiazine described a 
61% reduction of lesions size was observed in the 
classic treatment group versus 59% in the TMP/S 
group. Reaction to sulfadiazine therapy is observed in 
overall 5% of patients. The main side effects are crys-
talluria, disorders of hematopoietic system hypersen-
sitivity reaction nausea and vomiting and depression. 
The sulfadiazine cristalluria occurs in 1-4% of pa-
tients. The predisposing factors are a poor fluid in-
take, fever, diarrhoea, hypoalbuminuria and acidifi-
cation of the urine. Cofactors in AIDS patients are 
concomitant use of acyclovir, triamterene or primi-
done. The leukopenia or thrombocytemia occur in the 
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presence of interactions with the metabolism of folic 
acid. Folinic acid therapy is given three times a week 
to avoid leukopenia. Discontinuation of the therapy is 
recommended if the leukocytes are below 4 000 cells 
or if thrombocytes are below 100 000 cells. 
Maculo-papular rush appears in the presence of an 
allergy to sulfadiazine.  
Atovaquone therapy is used as second line 
treatment of toxoplasmosis. Atovaquone tablets 
750mg QID have been given for the treatment of 
Toxoplasma retinochoroiditis. Azithromycine is an 
alternative to classical therapy was proposed as an 
alternative therapy in the treatment of ocular 
toxoplasmosis. The efficacy of the drug was reported 
in cerebral toxoplasmosis in AIDS patients. The dos-
age used by Rothova et al was 250mg a day or 500mg 
every other day and therapy was associated with 
pyrimethamine 100mg on the first day that was fol-
lowed by 50mg a day. 
Prophylaxy of recurrence of toxoplamic reti-
nochoroiditis 
Long term intermittent Trimethoprim 
/Sulfamethoxazole treatments were used to prevent 
recurrences of toxoplasmic retinochoroiditis. Treat-
ment was given every three days with a dosage of 
60mg trimethoprim and 160mg Sulfamethoxazole. 
Recurrences were observed in only 6.6% versus 23.6% 
in the placebo group. However the results were not 
tested after 20 months of therapy and long term side 
effects are not known. 
Therapy of toxoplasmosis-associated ne-
ovascular lesions 
Toxoplasmosis-associated neovascular lesions 
are a rare complication of toxoplasmic retinochoroid-
itis. Photodynamic therapy with Visudyne was shown 
to block evolution in two out of three patients affected 
by neovascularization. Ranibizumab was shown to be 
a good alternative of therapy in three patients. Geno-
type studies and in vitro growth rates and resistance. 
Genotypic strains of toxoplasma gondii and re-
sistance to medication were recently suspected. De-
spite the fact that all clonage lineages can infect hu-
man beings, type II strains are predominant in Euro-
pean and North American population. Type III and 
recombinant I/III strains are predominant are pre-
dominant in South America. Various virulence has 
been demonstrated: Type I are highly virulent, type III 
strains are intermediate and type I/II are non virulent. 
Most of pharmacological studies were performed 
with RH strains (type I) which was used for its high 
capacity to grow in culture. A recent paper of Pascale 
Meneceur et al has shown that no significant differ-
ence in response to type I, II or III and one atypical 
strain was observed in the IC50 of the different strains 
towards pyrimethamine, sulfadiazine or atovaquone 
therapy. A correlation was observed between IC50 of 
pyrimethamine and strain growth rate. 
In conclusion, larges randomised clinical studies 
will be necessary to prove the advantage of one drug 
toward the other. These studies should be completed 
by strains analyses and comparison of potential re-
sistance toward the antitoxoplasmic drugs. 
 
 
Figure 1: Active retinitis area adjacent to previous cica-
tricial foci. 
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